Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CEO Jack A. Khattar Sells 125,000 Shares

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CEO Jack A. Khattar sold 125,000 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total value of $4,585,000.00. Following the completion of the sale, the chief executive officer now owns 926,172 shares of the company’s stock, valued at $33,971,988.96. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock traded up $0.20 during trading hours on Friday, hitting $36.60. The company’s stock had a trading volume of 578,615 shares, compared to its average volume of 452,714. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of 34.02 and a beta of 0.86. Supernus Pharmaceuticals, Inc. has a twelve month low of $24.46 and a twelve month high of $39.37. The firm has a fifty day moving average of $33.11 and a 200-day moving average of $30.63.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.25. The firm had revenue of $175.70 million for the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The company’s quarterly revenue was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.29) EPS. On average, sell-side analysts expect that Supernus Pharmaceuticals, Inc. will post 1.53 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Large investors have recently bought and sold shares of the stock. GAMMA Investing LLC boosted its position in shares of Supernus Pharmaceuticals by 97.1% during the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock worth $25,000 after acquiring an additional 398 shares in the last quarter. EntryPoint Capital LLC acquired a new position in shares of Supernus Pharmaceuticals during the 1st quarter worth about $43,000. Meeder Asset Management Inc. acquired a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth about $47,000. Innealta Capital LLC acquired a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth about $51,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Supernus Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after purchasing an additional 352 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.